NEW HAVEN, August 28, 2026, 05:12 (EDT)
- BioXcel sought Chapter 11 bankruptcy protection in Delaware on Thursday.
- Shares dropped by 62.4% to approximately $0.27 in premarket trading, with volume close to 975,000 shares.
- The petition states that estimated assets range between $10 million and $50 million.
- Estimated liabilities ranging from $100 million to $500 million take priority over common equity.
BioXcel Therapeutics Inc. (NASDAQ: BTAI) dropped nearly 62% ahead of Friday’s session following the company’s decision to seek Chapter 11 bankruptcy protection. The move changes a financing deadline into a court-led solvency assessment.
Investor focus remains on the capital structure. Reported liabilities are at least double the upper end of the stated asset range.
BTAI was last seen at approximately $0.27 as of 05:10 EDT, a drop from its Thursday close around $0.72. Premarket trading volume neared 975,000 shares premarket data.
The company submitted a filing to the U.S. Bankruptcy Court in Delaware on Thursday. The petition lists assets valued at between $10 million and $50 million, with liabilities ranging from $100 million to $500 million court-filing report.
The company filed after meeting a stringent lender deadline. A regulatory notice issued on August 24 set an August 28 cutoff for firm repayment or new capital arrangements Form 8-K exhibit.
| Investor measure | Latest figure | Why it matters |
|---|---|---|
| Premarket price | About $0.27 | Shares fall 62.4% |
| Premarket volume | About 975,000 | Significant activity indicates price discovery |
| Estimated assets | $10M–$50M | Bankruptcy filing cites this range |
| Estimated liabilities | $100M–$500M | Obligations outrank equity holders |
| Q2 2026 revenue | About $0.18M | Small operating footprint |
| Q2 2026 net loss | About $14.7M | Ongoing need for cash |
BioXcel previously cautioned that its restricted liquidity and debt commitments posed significant uncertainty regarding its ability to remain in business. As of March 31, the company reported approximately $17.2 million in cash, compared with a quarterly operating cash outflow of around $11.8 million.
Revenue for the second quarter totaled roughly $180,000, and net loss stood near $14.7 million. The shortfall left the company reliant on outside funding Reuters.
The core business focuses on IGALMI, an authorized sublingual therapy for acute agitation associated with schizophrenia or bipolar disorder. BioXcel has also worked to broaden at-home applications for BXCL501.
These assets might still hold value. Under Chapter 11, however, secured lenders and other creditors are prioritized before common shareholders.
Analyst targets set prior to the petition do not serve as relevant valuation references anymore. Investors must now focus on first-day motions, financing details, and any outlined sale procedures.
Nasdaq status is also a factor. An extended period below the $1 mark and the ongoing bankruptcy proceedings may result in further listing measures or trading limitations.
Risks: Current shares may face significant dilution or cancellation as a result of a reorganization plan. Although a contested asset sale might boost recoveries, creditors would receive payment prior to common shareholders.
